Albendazole-d₇

Albendazole-d₇ is intended for use as an internal standard for the quantification of albendazole (Item No. 23705) by GC- or LC-MS. Albendazole is an orally bioavailable benzimidazole anthelmintic that is active against a variety of helminths, including liver flukes, tapeworms, and roundworms.¹ It eliminates Trichostrongylus in the fourth stomach of cattle and sheep when orally administered at doses ranging from 2.5 to 10 mg/kg as well as other species in the fourth stomach and the small and large intestine. Albendazole (0.05% in the diet) protects mice against lethal infection with A. suum larvae. It also inhibits growth of HT-29 human colorectal cancer cells (IC₅₀ = 0.12 µM), halts the cell cycle at the G₂/M phase, and induces apoptosis. In an HT-29 mouse xenograft model, it inhibits peritoneal tumor growth when administered intraperitoneally at a dose of 150 mg/kg but not when administered orally.² Albendazole inhibits mammalian tubulin polymerization and inhibits binding of [³H]mebendazole to H. contortus L3 larval tubulin (IC₅₀s = 6.9 and 0.21 µM, respectively).³ Formulations containing albendazole have been used in the treatment of tapeworm infections and in a variety of nematode infections in livestock and pets.

WARNING This product is not for human or veterinary use.

1. Theodorides, V.J., Gyurik, R.J., Kingsbury, W.D., et al. Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and gastrointestinal roundworms. Experientia 32(6), 702-703 (1976).

2. Pourgholami, M.H., Akhter, J., Wang, L., et al. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: In vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother. Pharmacol. 55(5), 425-432 (2005).

3. Lacey, E. Mode of action of benzimidazoles. Parasitol. Today 6(4), 112-115 (1990).